Strong demand has stoked high hopes for Eli Lilly’s Mounjaro, but insurance companies are slow to get on board, sparking fears among investors.
You are here: Home / Eli Lilly investors spooked by weak Mounjaro sales, but it’s the obesity drug approval that will unlock its value